Biotech Values

[Biowatch]

BTW, the Mass General doc SPPI quotes in the PR is on the scientific advisory board for ALTI, so I would *hope* he likes the deal.

From the ALTI website:

>>Award-winning Harvard Medical School Professor and Kidney Dialysis Research Specialist Brings Focused Expertise to Advisory Board

RENO, NV – October 7, 2004 – Altair Nanotechnologies, Inc. (NASDAQ: ALTI) today announced that Dr. Ravi I. Thadhani has joined the company’s Scientific Advisory Board. Dr. Thadhani, an award-winning clinical instructor, researcher, and medical practitioner, will lend his expertise to the company’s life sciences division, in particular the ongoing development of nano-based pharmaceutical and biotechnology applications.

“I am enthusiastic to be joining Altair’s Scientific Advisory Board at this particular juncture in their business strategy,” said Dr. Thadhani. “Nanotechnology-based research has already shown tremendous promise for applications in traditional medicine and I anticipate nanotechnology to truly change the future of all aspects of life sciences. I look forward to working closely with the Altair team and board as they continue development of their drug candidate for end stage renal disease as well as their advanced drug delivery systems.”

“The appointment of Dr. Thadhani to our Scientific Advisory Board will prove invaluable to our life sciences efforts,” said Altair Chief Executive Officer Dr. Alan J. Gotcher. “Ravi is an established clinician, with widely regarded expertise in researching and developing new therapeutic techniques for kidney-related ailments including chronic and acute renal failure. We are honored to have him join our board.”

The Scientific Advisory Board provides a wealth of scientific and industrial technology expertise that Altair’s management, research and product development teams can draw upon as the company drives toward commercialization of nanotechnology products.<<